An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

@article{Antman1993AnIP,
  title={An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.},
  author={K S Antman and John C Crowley and Stanley P. Balcerzak and Saul E. Rivkin and Geoffrey Roger Weiss and Anthony Elias and Ronald B. Natale and Richard M. Cooper and Bart Barlogie and Donald L. Trump},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1993},
  volume={11 7},
  pages={1276-85}
}
PURPOSE AND METHODS Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas. Ifosfamide is active in sarcomas that have failed to respond to a doxorubicin-based regimen. This study was designed to determine if ifosfamide added to doxorubicin and DTIC (ADI) significantly effects toxicity, response rate, and survival. Patients with measurable metastatic or unresectable sarcoma were randomized to receive AD or ADI. Patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
121 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 121 extracted citations

Similar Papers

Loading similar papers…